Citations (95)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (95)
Fei Zeng, Karsten Parker, Yanqiang Zhan, Matthew Miller & Meng-Yang Zhu. (2023) Upregulated DNA Damage-Linked Biomarkers in Parkinson's Disease Model Mice. ASN Neuro 15, pages 175909142311520.
Crossref
Crossref
Rachel M. Wise, Annika Wagener, Urban M. Fietzek, Thomas Klopstock, Eugene V. Mosharov, Fabio A. Zucca, David Sulzer, Luigi Zecca & Lena F. Burbulla. (2022) Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders. Neurobiology of Disease 175, pages 105920.
Crossref
Crossref
Tracy D. Zhang, Scott C. Kolbe, Leah C. Beauchamp, Ella K. Woodbridge, David I. Finkelstein & Emma L. Burrows. (2022) How Well Do Rodent Models of Parkinson’s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review. Biomedicines 10:12, pages 3026.
Crossref
Crossref
Sabina Marciano, Tudor M. Ionescu, Ran Sing Saw, Rachel Y. Cheong, Deniz Kirik, Andreas Maurer, Bernd J. Pichler & Kristina Herfert. (2022) Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. Proceedings of the National Academy of Sciences 119:40.
Crossref
Crossref
Hildur Sóley Sveinsdóttir, Amanda Decker, Christian Christensen, Pablo Botella Lucena, Haraldur Þorsteinsson, Elena Richert, Valerie Helene Maier, Robert Cornell & Karl Ægir Karlsson. (2022) Motility phenotype in a zebrafish vmat2 mutant. PLOS ONE 17:1, pages e0259753.
Crossref
Crossref
Eugene V. Mosharov. 2022. Handbook of Neurotoxicity. Handbook of Neurotoxicity
291
311
.
Marta M. Morawska, Carlos G. Moreira, Varun R. GindePhilipp O. Valko, Tobias Weiss, Fabian BücheleLukas L. Imbach, Sophie MasneufSedef Kollarik, Natalia PrymaczokJuan A. GerezRoland RiekChristian R. Baumann & Daniela Noain. (2021) Slow-wave sleep affects synucleinopathy and regulates proteostatic processes in mouse models of Parkinson’s disease. Science Translational Medicine 13:623.
Crossref
Crossref
Gian Pietro Serra, Adriane Guillaumin, Sylvie Dumas, Bianca Vlcek & Åsa Wallén-Mackenzie. (2021) Midbrain Dopamine Neurons Defined by TrpV1 Modulate Psychomotor Behavior. Frontiers in Neural Circuits 15.
Crossref
Crossref
Fiona Limanaqi, Carla L. Busceti, Roberta Celli, Francesca Biagioni & Francesco Fornai. (2021) Autophagy as a gateway for the effects of methamphetamine: From neurotransmitter release and synaptic plasticity to psychiatric and neurodegenerative disorders. Progress in Neurobiology 204, pages 102112.
Crossref
Crossref
Shreyas Bhat, Ali El-Kasaby, Michael Freissmuth & Sonja Sucic. (2021) Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits. Pharmacology & Therapeutics 222, pages 107785.
Crossref
Crossref
Carlie A. Black, Meghan L. Bucher, Joshua M. Bradner, Lauren Jonas, Kenny Igarza & Gary W. Miller. (2020) Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters. Chemical Research in Toxicology 34:5, pages 1256-1264.
Crossref
Crossref
Felipe Dalvi-Garcia, Luis L. Fonseca, Ana Tereza R. Vasconcelos, Cecilia Hedin-Pereira & Eberhard O. Voit. (2021) A model of dopamine and serotonin-kynurenine metabolism in cortisolemia: Implications for depression. PLOS Computational Biology 17:5, pages e1008956.
Crossref
Crossref
Kui Cui, Fan Yang, Turan Tufan, Muhammad U. Raza, Yanqiang Zhan, Yan Fan, Fei Zeng, Russell W. Brown, Jennifer B. Price, Thomas C. Jones, Gary W. Miller & Meng-Yang Zhu. (2021) Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice. ASN Neuro 13, pages 175909142110097.
Crossref
Crossref
Eugene V. Mosharov. 2021. Handbook of Neurotoxicity. Handbook of Neurotoxicity
1
22
.
Suzanne O. Nolan, Jennifer E. Zachry, Amy R. Johnson, Lillian J. Brady, Cody A. Siciliano & Erin S. Calipari. (2020) Direct dopamine terminal regulation by local striatal microcircuitry. Journal of Neurochemistry 155:5, pages 475-493.
Crossref
Crossref
Carlos G. Moreira, Marta M. Morawska, Aron Baumann, Sophie Masneuf, Michael Linnebank, Michael Sommerauer, Hans-Peter Landolt, Daniela Noain & Christian R. Baumann. (2020) Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice. Neuropharmacology 181, pages 108353.
Crossref
Crossref
Niclas König, Zisis Bimpisidis, Sylvie Dumas & Åsa Wallén-Mackenzie. (2020) Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse. Frontiers in Behavioral Neuroscience 14.
Crossref
Crossref
Daisuke Sakano, Fumiya Uefune, Hiraku Tokuma, Yuki Sonoda, Kumi Matsuura, Naoki Takeda, Naomi Nakagata, Kazuhiko Kume, Nobuaki Shiraki & Shoen Kume. (2020) VMAT2 Safeguards β-Cells Against Dopamine Cytotoxicity Under High-Fat Diet–Induced Stress. Diabetes 69:11, pages 2377-2391.
Crossref
Crossref
Rachel C. Branco, James P. Burkett, Carlie A. Black, Emily Winokur, William Ellsworth, Rohan K. Dhamsania, Kelly M. Lohr, Jason P. Schroeder, David Weinshenker, Tanja Jovanovic & Gary W. Miller. (2020) Vesicular monoamine transporter 2 mediates fear behavior in mice. Genes, Brain and Behavior 19:5.
Crossref
Crossref
Song Jiang, Stefan Berger, Yajuan Hu, Dusan Bartsch & Yanghua Tian. (2020) Alterations of the Motor and Olfactory Functions Related to Parkinson’s Disease in Transgenic Mice With a VMAT2-Deficiency in Dopaminergic Neurons. Frontiers in Neuroscience 14.
Crossref
Crossref
E.G. Landis, M.A. Chrenek, R. Chakraborty, R. Strickland, M. Bergen, V. Yang, P.M. Iuvone & M.T. Pardue. (2020) Increased endogenous dopamine prevents myopia in mice. Experimental Eye Research 193, pages 107956.
Crossref
Crossref
E. R. Mingazov & M. V. Ugryumov. (2019) Molecular Markers of Dopamine Transport in Nigrostriatal Dopaminergic Neurons as an Index of Neurodegeneration and Neuroplasticity. Neurochemical Journal 13:1, pages 43-48.
Crossref
Crossref
Clement C. Zai, Miriam S. Maes, Arun K. Tiwari, Gwyneth C. Zai, Gary Remington & James L. Kennedy. (2018) Genetics of tardive dyskinesia: Promising leads and ways forward. Journal of the Neurological Sciences 389, pages 28-34.
Crossref
Crossref
Marc Morissette, Nicolas Morin, Claude Rouillard & Thérèse Di Paolo. (2018) Membrane cholesterol removal and replenishment affect rat and monkey brain monoamine transporters. Neuropharmacology 133, pages 289-306.
Crossref
Crossref
Michael R. Post, Ori J. Lieberman & Eugene V. Mosharov. (2018) Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?. Frontiers in Neuroscience 12.
Crossref
Crossref
David S. Goldstein & Irwin J. Kopin. (2017) Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky. Cellular and Molecular Neurobiology 38:1, pages 13-24.
Crossref
Crossref
Elsa Isingrini, Chloé Guinaudie, Léa C Perret, Quentin Rainer, Luc Moquin, Alain Gratton & Bruno Giros. (2017) Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson’s disease motor symptoms without neuronal degeneration in adult mice. Scientific Reports 7:1.
Crossref
Crossref
Amy R. Dunn, Kristen A. StoutMinagi OzawaKelly M. LohrCarlie A. HoffmanAlison I. BernsteinYingjie LiMinzheng WangCarmelo SgobioNamratha SastryHuaibin CaiW. Michael CaudleGary W. Miller. (2017) Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proceedings of the National Academy of Sciences 114:11.
Crossref
Crossref
Kelly M. Lohr, Shababa T. Masoud, Ali Salahpour & Gary W. Miller. (2017) Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. European Journal of Neuroscience 45:1, pages 20-33.
Crossref
Crossref
Aron Baumann, Carlos G. Moreira, Marta M. Morawska, Sophie Masneuf, Christian R. Baumann & Daniela Noain. (2016) Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice. Frontiers in Human Neuroscience 10.
Crossref
Crossref
S V Trossbach, V Bader, L Hecher, M E Pum, S T Masoud, I Prikulis, S Schäble, M A de Souza Silva, P Su, B Boulat, C Chwiesko, G Poschmann, K Stühler, K M Lohr, K A Stout, A Oskamp, S F Godsave, A Müller-Schiffmann, T Bilzer, H Steiner, P J Peters, A Bauer, M Sauvage, A J Ramsey, G W Miller, F Liu, P Seeman, N J Brandon, J P Huston & C Korth. (2016) Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits. Molecular Psychiatry 21:11, pages 1561-1572.
Crossref
Crossref
Kai-Cheng Hsu & Feng-Sheng Wang. (2016) Fuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine Deficiency. PLOS ONE 11:10, pages e0164589.
Crossref
Crossref
Kelly M. Lohr, Merry Chen, Carlie A. Hoffman, Miranda J. McDaniel, Kristen A. Stout, Amy R. Dunn, Minzheng Wang, Alison I. Bernstein & Gary W. Miller. (2016) Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. Toxicological Sciences 153:1, pages 79-88.
Crossref
Crossref
David Sulzer, Stephanie J. Cragg & Margaret E. Rice. (2016) Striatal dopamine neurotransmission: Regulation of release and uptake. Basal Ganglia 6:3, pages 123-148.
Crossref
Crossref
Nian Xiong, Nuomin Li, Eden Martin, Jinlong Yu, Jie Li, Jing Liu, David Yue-Wei Lee, Ole Isacson, Jeffery Vance, Hong Qing, Tao Wang & Zhicheng Lin. (2016) hVMAT2: A Target of Individualized Medication for Parkinson’s Disease. Neurotherapeutics 13:3, pages 623-634.
Crossref
Crossref
Li Wang, Yunxiao Kang, Guoliang Zhang, Yingbo Zhang, Rui Cui, Wensheng Yan, Huibing Tan, Shuangcheng Li, Baiyila Wu, Huixian Cui & Geming Shi. (2016) Deficits in coordinated motor behavior and in nigrostriatal dopaminergic system ameliorated and VMAT2 expression up-regulated in aged male rats by administration of testosterone propionate. Experimental Gerontology 78, pages 1-11.
Crossref
Crossref
Daniela B Pereira, Yvonne Schmitz, József Mészáros, Paolomi Merchant, Gang Hu, Shu Li, Adam Henke, José E Lizardi-Ortiz, Richard J KarpowiczJrJr, Travis J Morgenstern, Mark S Sonders, Ellen Kanter, Pamela C Rodriguez, Eugene V Mosharov, Dalibor Sames & David Sulzer. (2016) Fluorescent false neurotransmitter reveals functionally silent dopamine vesicle clusters in the striatum. Nature Neuroscience 19:4, pages 578-586.
Crossref
Crossref
D. Sulzer, S.J. Cragg & M.E. Rice. 2016. Handbook of Basal Ganglia Structure and Function, Second Edition. Handbook of Basal Ganglia Structure and Function, Second Edition
373
402
.
Anderson H.F.F. Leão, Aldair J. Sarmento-Silva, José R. Santos, Alessandra M. Ribeiro & Regina H. Silva. (2015) Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model. Brain Pathology 25:4, pages 377-390.
Crossref
Crossref
Martin Larhammar, Kalicharan Patra, Martina Blunder, Lina Emilsson, Christiane Peuckert, Emma Arvidsson, Daniel Rönnlund, Julia Preobraschenski, Carolina Birgner, Christoph Limbach, Jerker Widengren, Hans Blom, Reinhard Jahn, Åsa Wallén-Mackenzie & Klas Kullander. (2015) SLC10A4 Is a Vesicular Amine-Associated Transporter Modulating Dopamine Homeostasis. Biological Psychiatry 77:6, pages 526-536.
Crossref
Crossref
David S. Goldstein, Irwin J. Kopin & Yehonatan Sharabi. (2014) Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacology & Therapeutics 144:3, pages 268-282.
Crossref
Crossref
David S. Goldstein, Patricia Sullivan, Courtney Holmes, Gary W. Miller, Yehonatan Sharabi & Irwin J. Kopin. (2014) A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease. Journal of Neurochemistry 131:2, pages 219-228.
Crossref
Crossref
Kelly M. LohrAlison I. BernsteinKristen A. StoutAmy R. DunnCarlos R. LazoShawn P. AlterMinzheng WangYingjie LiXueliang FanEllen J. HessHong Yi, Laura M. Vecchio, David S. Goldstein, Thomas S. GuillotAli Salahpour & Gary W. Miller. (2014) Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences 111:27, pages 9977-9982.
Crossref
Crossref
B. Torres & A.E. Ruoho. (2014) N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux. Neuroscience 259, pages 194-202.
Crossref
Crossref
Tonya N. Taylor, Shawn P. Alter, Minzheng Wang, David S. Goldstein & Gary W. Miller. (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76, pages 97-105.
Crossref
Crossref
F.S. Hall, K. Itokawa, A. Schmitt, R. Moessner, I. Sora, K.P. Lesch & G.R. Uhl. (2014) Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. Neuropharmacology 76, pages 146-155.
Crossref
Crossref
Eugene V. Mosharov. 2014. Handbook of Neurotoxicity. Handbook of Neurotoxicity
973
993
.
Marco Bisaglia, Elisa Greggio, Mariano Beltramini & Luigi Bubacco. (2013) Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. The FASEB Journal 27:6, pages 2101-2110.
Crossref
Crossref
Laura Brighina, Chiara Riva, Francesca Bertola, Enrico Saracchi, Silvia Fermi, Stefano Goldwurm & Carlo Ferrarese. (2013) Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease. Neurobiology of Aging 34:6, pages 1712.e9-1712.e13.
Crossref
Crossref
Jennifer J. Rilstone, Reem A. Alkhater & Berge A. Minassian. (2013) Brain Dopamine–Serotonin Vesicular Transport Disease and Its Treatment. New England Journal of Medicine 368:6, pages 543-550.
Crossref
Crossref
Irene Llorente-Folch, Ignasi Sahún, Laura Contreras, María José Casarejos, Josep María Grau, Takeyori Saheki, María Angeles Mena, Jorgina Satrústegui, Mara Dierssen & Beatriz Pardo. (2013) AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. Journal of Neurochemistry 124:3, pages 347-362.
Crossref
Crossref
Ayse Ulusoy, Tomas Björklund, Kerstin Buck & Deniz Kirik. (2012) Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. Neurobiology of Disease 47:3, pages 367-377.
Crossref
Crossref
E. Danielle Dean, Lydia M. Mexas, Natalie L. Cápiro, Jeanne E. McKeon, Mahlon R. DeLong, Kurt D. Pennell, Jonathan A. Doorn, Vin Tangpricha, Gary W. Miller & Marian L. Evatt. (2012) 25-Hydroxyvitamin D Depletion Does Not Exacerbate MPTP-Induced Dopamine Neuron Damage in Mice. PLoS ONE 7:7, pages e39227.
Crossref
Crossref
Esmee S. B. van Kleef, Patricia Gaspar & Alexandre Bonnin. (2012) Insights into the complex influence of 5-HT signaling on thalamocortical axonal system development. European Journal of Neuroscience 35:10, pages 1563-1572.
Crossref
Crossref
Donna M. Crabtree & Jianhua Zhang. (2012) Genetically engineered mouse models of Parkinson's disease. Brain Research Bulletin 88:1, pages 13-32.
Crossref
Crossref
Zhen Qi, Gary W. Miller & Eberhard O. Voit. 2012. Systems Biology of Parkinson's Disease. Systems Biology of Parkinson's Disease
151
171
.
Zhigang Zhou, Jeeyong Kim, Ryan Insolera, Xiangmin Peng, David J. Fink & Marina Mata. (2011) Rho GTPase regulation of α-synuclein and VMAT2: Implications for pathogenesis of Parkinson's disease. Molecular and Cellular Neuroscience 48:1, pages 29-37.
Crossref
Crossref
Tonya N. Taylor, W. Michael Caudle & Gary W. Miller. (2011) VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease 2011, pages 1-9.
Crossref
Crossref
Zhicheng Lin, Juan J. Canales, Thröstur Björgvinsson, Morgane Thomsen, Hong Qu, Qing-Rong Liu, Gonzalo E. Torres & S. Barak Caine. 2011. The Brain as a Drug Target. The Brain as a Drug Target
1
46
.
Shuji Iritani, Hirotaka Sekiguchi, Chikako Habuchi, Takao Hikita, Shinichiro Taya, Kozo Kaibuchi & Norio Ozaki. (2010) Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal region of genetic animal model of schizophrenia. Synapse 64:12, pages 948-953.
Crossref
Crossref
Shuji Iritani, Hirotaka Sekiguchi, Chikako Habuchi, Youta Torii, Shinnosuke Yamada, Yukari Waki, Yukihiro Noda, Hiroshi Furukawa, Toshitaka Nabeshima & Norio Ozaki. (2010) Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice. Neuroscience Research 68:2, pages 125-130.
Crossref
Crossref
Hakeem O. Lawal, Hui-Yun Chang, Ashley N. Terrell, Elizabeth S. Brooks, Dianne Pulido, Anne F. Simon & David E. Krantz. (2010) The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons. Neurobiology of Disease 40:1, pages 102-112.
Crossref
Crossref
Gessica Sala, Laura Brighina, Enrico Saracchi, Silvia Fermi, Chiara Riva, Veronica Carrozza, Marta Pirovano & Carlo Ferrarese. (2010) Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson’s disease. Journal of Neural Transmission 117:9, pages 1093-1098.
Crossref
Crossref
Ichiro Sora, BingJin Li, Moe Igari, F. Scott Hall & Kazutaka Ikeda. (2010) Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Annals of the New York Academy of Sciences 1187:1, pages 218-246.
Crossref
Crossref
Zhen Qi, Gary W. Miller & Eberhard O. Voit. (2009) Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals. Synapse 63:12, pages 1133-1142.
Crossref
Crossref
Anthony C. Vernon. (2009) Mice with Reduced Vesicular Monoamine Storage Content Display Nonmotor Features of Parkinson's Disease: Table 1.. The Journal of Neuroscience 29:41, pages 12842-12844.
Crossref
Crossref
Frank M. J. JacobsAnnemarie J. A. van der LindenYuhui WangLars von OerthelHei Sook SulJ. Peter H. BurbachMarten P. Smidt. (2009)
Identification of
Dlk1, Ptpru
and
Klhl1
as novel Nurr1 target genes in meso-diencephalic dopamine neurons
. Development 136:14, pages 2363-2373.
Crossref
Crossref
George F.G. Allen, John M. Land & Simon J.R. Heales. (2009) A new perspective on the treatment of aromatic l-amino acid decarboxylase deficiency. Molecular Genetics and Metabolism 97:1, pages 6-14.
Crossref
Crossref
Sara S. Mason, Kevin B. Baker, Kristina W. Davis, Vladimir M. Pogorelov, Murtaza M. Malbari, Ruth Ritter, Stephen P. Wray, Brenda Gerhardt, Thomas H. Lanthorn & Katerina V. Savelieva. (2009) Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. European Journal of Pharmacology 602:2-3, pages 306-315.
Crossref
Crossref
H. Fei & D. E. Krantz. 2009. Handbook of Neurochemistry and Molecular Neurobiology. Handbook of Neurochemistry and Molecular Neurobiology
87
137
.
Thomas S. Guillot, Kennie R. Shepherd, Jason R. Richardson, Min Z. Wang, Yingjie Li, Piers C. Emson & Gary W. Miller. (2008) Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. Journal of Neurochemistry 106:5, pages 2205-2217.
Crossref
Crossref
Zhen Qi, Gary W. Miller & Eberhard O. Voit. (2008) Computational Systems Analysis of Dopamine Metabolism. PLoS ONE 3:6, pages e2444.
Crossref
Crossref
W. Michael Caudle, Rebecca E. Colebrooke, Piers C. Emson & Gary W. Miller. (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends in Neurosciences 31:6, pages 303-308.
Crossref
Crossref
Reza M. Salek, Rebecca E. Colebrooke, Robin Macintosh, Patrick J. Lynch, Brian C. Sweatman, Piers C. Emson & Julian L. Griffin. (2007) A Metabolomic Study of Brain Tissues from Aged Mice with Low Expression of the Vesicular Monoamine Transporter 2 (VMAT2) Gene. Neurochemical Research 33:2, pages 292-300.
Crossref
Crossref
Jun Tang Guo, An Qi Chen, Qi Kong, Hua Zhu, Chun Mei Ma & Chuan Qin. (2007) Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells. Cellular and Molecular Neurobiology 28:1, pages 35-47.
Crossref
Crossref
Sandra Vergo, Jens Leander Johansen, Marcel Leist & Julie Lotharius. (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Research 1185, pages 18-32.
Crossref
Crossref
W. Michael Caudle, Jason R. Richardson, Min Z. Wang, Tonya N. Taylor, Thomas S. Guillot, Alison L. McCormack, Rebecca E. Colebrooke, Donato A. Di Monte, Piers C. Emson & Gary W. Miller. (2007) Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration. The Journal of Neuroscience 27:30, pages 8138-8148.
Crossref
Crossref
Hideko Yamamoto, Etsuko Kamegaya, Yoko Hagino, Kazuhide Imai, Akihiro Fujikawa, Kohei Tamura, Tomoyuki Enokiya, Toshifumi Yamamoto, Takao Takeshima, Hisashi Koga, George R. Uhl, Kazutaka Ikeda & Ichiro Sora. (2007) Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochemistry International 51:2-4, pages 237-244.
Crossref
Crossref
R.E. Colebrooke, P.M. Chan, P.J. Lynch, K. Mooslehner & P.C. Emson. (2007) Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene. Brain Research 1152, pages 10-16.
Crossref
Crossref
Tzu-Kang Sang, Hui-Yun Chang, George M. Lawless, Anuradha Ratnaparkhi, Lisa Mee, Larry C. Ackerson, Nigel T. Maidment, David E. Krantz & George R. Jackson. (2007)
A
Drosophila
Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine
. The Journal of Neuroscience 27:5, pages 981-992.
Crossref
Crossref
Shinji Higashi, Darren J. Moore, Rebecca E. Colebrooke, Saskia Biskup, Valina L. Dawson, Heii Arai, Ted M. Dawson & Piers C. Emson. (2007) Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry 100:2, pages 368-381.
Crossref
Crossref
Guangrong Zheng, Linda P. Dwoskin & Peter A. Crooks. (2006) Vesicular monoamine transporter 2: Role as a novel target for drug development. The AAPS Journal 8:4, pages E682-E692.
Crossref
Crossref
Rebecca E. Colebrooke, Trevor Humby, Patrick J. Lynch, Daniel P. McGowan, Jing Xia & Piers C. Emson. (2006) Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. European Journal of Neuroscience 24:9, pages 2622-2630.
Crossref
Crossref
W. Michael Caudle, Jason R. Richardson, Kristin C. Delea, Thomas S. Guillot, Minzheng Wang, Kurt D. Pennell & Gary W. Miller. (2006) Polychlorinated Biphenyl–Induced Reduction of Dopamine Transporter Expression as a Precursor to Parkinson's Disease–Associated Dopamine Toxicity. Toxicological Sciences 92:2, pages 490-499.
Crossref
Crossref
Charles E. Glatt, Angelika D. Wahner, Daniel J. White, Andres Ruiz-Linares & Beate Ritz. (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Human Molecular Genetics 15:2, pages 299-305.
Crossref
Crossref
H-Y Chang, A Grygoruk, E S Brooks, L C Ackerson, N T Maidment, R J Bainton & D E Krantz. (2005) Overexpression of the Drosophila vesicular monoamine transporter increases motor activity and courtship but decreases the behavioral response to cocaine. Molecular Psychiatry 11:1, pages 99-113.
Crossref
Crossref
S.A. Lloyd, C.J. Faherty & R.J. Smeyne. (2006) Adult and in utero exposure to cocaine alters sensitivity to the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 137:3, pages 905-913.
Crossref
Crossref
Amy K. Jassen, Jeffrey M. Brown, Helen N. Panas, Gregory M. Miller, Danqing Xiao & Bertha K. Madras. (2005) Variants of the primate vesicular monoamine transporter-2. Molecular Brain Research 139:2, pages 251-257.
Crossref
Crossref
Tatyana D Sotnikova, Jean-Martin Beaulieu, Larry S Barak, William C Wetsel, Marc G Caron & Raul R Gainetdinov. (2005) Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease. PLoS Biology 3:8, pages e271.
Crossref
Crossref
Carol X.-Q. Chen, Steven Y. Huang, Limei Zhang & Yong-Jian Liu. (2005) Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells. Neurobiology of Disease 19:3, pages 419-426.
Crossref
Crossref
Benjamin G. Croft, Gabriel D. Fortin, Amadou T. Corera, Robert H. Edwards, Alain Beaudet, Louis-Eric Trudeau & Edward A. Fon. (2005) Normal Biogenesis and Cycling of Empty Synaptic Vesicles in Dopamine Neurons of Vesicular Monoamine Transporter 2 Knockout Mice. Molecular Biology of the Cell 16:1, pages 306-315.
Crossref
Crossref
Jyoti Patel, Katrin A. Mooslehner, Pok Man Chan, Piers C. Emson & Jonathan A. Stamford. (2003) Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. Journal of Neurochemistry 85:4, pages 898-910.
Crossref
Crossref
F Scott Hall, I Sora & G R Uhl. (2002) Sex-Dependent Modulation of Ethanol Consumption in Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Knockout Mice. Neuropsychopharmacology 28:4, pages 620-628.
Crossref
Crossref
Erica L. Unger, Pascale Mazzola-Pomietto, Dennis L. Murphy & Anne M. Andrews. (2002)
2′-NH
2
-MPTP [1-Methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2′-CH
3
-MPTP [1-Methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine]
. Journal of Pharmacology and Experimental Therapeutics 303:2, pages 527-533.
Crossref
Crossref
Mara L Cordeiro, Cameron B Gundersen & Joy A Umbach. (2002) Lithium ions modulate the expression of VMAT2 in rat brain. Brain Research 953:1-2, pages 189-194.
Crossref
Crossref